Kurs
-10,49%
Kurs
-10,49%
Open
30,00
High
30,00
Low
26,70
Close
26,80
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
58,9 MNOK
Likviditet
58,9 MNOK
Rel. mcap
6,54%
Antal aktier
2 120 193
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2026-02-25 | 06:30 | Bokslutskommuniké 2025 |
| 2025-11-26 | 00:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 00:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-22 | N/A | Årsstämma |
| 2025-05-14 | 00:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-26 | 06:30 | Bokslutskommuniké 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-21 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-15 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-12 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2023-05-11 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-16 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-13 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2022-05-12 | - | Årsstämma |
| 2022-03-31 | - | Bokslutskommuniké 2021 |
| 2021-12-22 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-06 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-21 | - | Bokslutskommuniké 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-07 | - | Split NYKD 1:5 |
| 2020-07-06 | - | Extra Bolagsstämma |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-22 | - | Extra Bolagsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2023-04-20 07:00:00
Oslo, Norway, April 20, 2023 - The Board of Directors of Nykode Therapeutics ASA
(OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the
discovery and development of novel immunotherapies, hereby calls for the Annual
General Meeting to be held at meeting room FORUM - Building H, Floor 0 in
Gaustadalléen 21, Oslo, Norway at 10:00 CET on May 11, 2023.
All documents regarding the Annual General Meeting are available at the
Company's website:
www.nykode.com/investors/corporate-governance/annual-general-meeting/
For further information, please see the Company's website or contact CFO Harald
Gurvin. Please see below for contact details.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which have been shown to induce
broad, strong and long-lasting antigen specific immune responses which
correlates with clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive safety and efficacy results from its Phase 2 trial for the
treatment of cervical cancer